Clinical trials: Elderly Cancer Patients
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
This phase I trial tests the safety, side effects and best dose of epcoritamab alone and epcoritamab with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R- mini-CHP) for the treatment of…
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT07714421
- Testing
- Biospecimen Collection, Computed Tomography, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colon Cancer, Rectal Cancer
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
This is a prospective, multicentre, cohort study. For cohort 1(CGA cohort), experimental cohort, older or Frail patients with metastatic colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive…
- Trial name
- NCT06665087
- Testing
- Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody
- Volunteers
- 110 people
- Sponsor
- Fudan University
Diffuse Large B-Cell Lymphoma (DLBCL)
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
- Trial name
- NCT07493148
- Testing
- Chidamide, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ou Bai, MD/PHD
Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, with 25% of HNSCC patients diagnosed at over 70 years of age. As the population ages, it is expected that by 2030, this proportion will exceed 60%.
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
- Trial name
- HNSCC (NCT06768125)
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Acute Myeloid Leukemia
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Elderly patients with acute myeloid leukemia (AML) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders.
- Trial name
- NCT06571825
- Testing
- Venetoclax, Allogeneic transplant
- Where
- China
- Volunteers
- 118 people
- Sponsor
- He Huang
Polycystic Ovary Syndrome
Effect of Metformin and Probiotics in Reproductive-aged Patients With Polycystic Ovary Syndrome
The purpose of this clinical trial is to evaluate the safety and effectiveness on the clinical and biological parameters of reproductive-aged PCOS women after a 12-week metformin and/or probiotics administration.
- Trial name
- NCT03336840
- Testing
- Metformin tablets, ProMetS probiotics powder, 1. Metformin tablets; 2. ProMetS probiotics powder
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Leukemia
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354276
- Testing
- cytarabine, laromustine
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- Vion Pharmaceuticals
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Cancer
Antineoplastic Drugs in Elderly Patients
The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend…
- Trial name
- NCT05467189
- Testing
- Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shandong University
Patients Aged 50-75 and Requiring Colonoscopy
The French Gut-colo
Colorectal cancer (CRC) is the second most common type of cancer worldwide. The European Union recommends national CRC screening for people aged between 50 and 74.
- Trial name
- NCT06174233
- Where
- France
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Head and Neck Squamous Cell Carcinoma
Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC
Randomized comparison between standard radiotherapy and hypofractionated split course schedule. Compared to standard radiotherapy, the investigators expect that hypofractionated split course (interruption of 2 weeks) radiotherapy…
- Trial name
- ELAN-RT (NCT01864850)
- Testing
- Standard RT, Hypofractionated RT
- Where
- 2 sites in France, Monaco
- Volunteers
- 202 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Cancer, Elderly Patients
Modification of the Quality of Life Based on Objective Geriatric Tests
The analysis of this study will achieve an improvement in the management of patients over 70 years with adaptation of chemotherapy regimens after analysis of the subject and its psychosocial environment.
- Trial name
- MEGERIA (NCT02873533)
- Testing
- geriatric care and longitudinal follow up
- Where
- France
- Volunteers
- 76 people
- Sponsor
- Centre Antoine Lacassagne
Lymphoma
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00060385
- Testing
- CHOP regimen, EPOCH regimen, cyclophosphamide
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Single Fraction Elderly Breast Irradiation (SiFEBI)
Irradiation and Accelerated Partial Breast (IPAS) to this day remains a therapeutic concept whose validity is being assessed on its non-inferiority in terms of local control compared to whole breast irradiation.
- Trial name
- SIFEBI (NCT01727011)
- Testing
- IPAS
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Antoine Lacassagne
Elderly, Malignant Tumor
Epidural Anesthesia-analgesia and Long-term Outcome
Surgical resection is one of the most important treatments for resectable cancer; on the other hand, cancer recurrence and/or metastasis are the major reasons of treatment failure.
- Conditions
- Elderly, Malignant Tumor, Surgical Resection, Epidural Anesthesia
- Trial name
- NCT03012945
- Testing
- Combined epidural-general anesthesia, General anesthesia
- Where
- 5 sites in China
- Volunteers
- 1,802 people
- Sponsor
- Peking University First Hospital
Osteosarcoma, Neoplasms, Connective Tissue
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Two cycles of neoadjuvant three-component chemotherapy according to the MAP prototoc: Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration.
- Conditions
- Osteosarcoma, Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Sarcoma
- Trial name
- NCT05057130
- Testing
- Doxorubicin, Cisplatin, Methotrexate, Doxorubicin, Cisplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Cancer
Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00002498
- Testing
- CMF regimen, cyclophosphamide, fluorouracil
- Where
- 2 sites in Netherlands
- Sponsor
- Leiden University Medical Center
Colorectal Cancer, Oncologic Complications
The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer
The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer.
- Conditions
- Colorectal Cancer, Oncologic Complications, Comprehensive Geriatric Assessment, Vestibular Rehabilitation
- Trial name
- SaVe (NCT05710809)
- Testing
- Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement
- Where
- 2 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Myeloid Leukemia
Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy
Standard therapy with Imatinib (IM) significantly prolongs the survival of Ph+CML patients who obtain a complete cytogenetic response (CCgR).
- Trial name
- INTERIM0407 (NCT00858806)
- Testing
- Imatinib
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- Università degli Studi di Brescia
Small Cell Lung Cancer, PEG-rhG-CSF
PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy
Evaluation of the efficacy and safety of Jinyouli in preventing neutropenia in multiple chemotherapy cycles in elderly patients with small cell lung cancer through a multicenter, open, one-arm study Subjects with newly diagnosed…
- Trial name
- NCT03776604
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 61 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.